Nafamostat Mesylate
Phase 3Small molecule
Nafamostat Mesylate is one of 55 small molecule programs targeting Sepsis. It is currently in Phase 3.
2
Indications
7
Total Trials
4
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
100 competitors in Sepsis
#DrugCompanyPhaseTrials
1Dobutrex
PfizerPhase 2
Gleevec
NovartisPhase 2
Proamatine
TakedaPhase 2
Antibiotics
MMelinta Therapeutics, Inc.
Phase 3
N-Acetylcysteine (NAC) Treatment
TThe First Affiliated Hospital of Soochow University
Phase 3
Decadron
AAspen Global Incorporated
Phase 2
G-CSF
AArog Pharmaceuticals, Inc.
Phase 2
Nafamostat Mesylate
EEnsysce Biosciences
Phase 3
Hydrocortisone Administration
UUniversity of Virginia
Phase 3
Simdax
Orion Corporation, Orion PharmaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sepsis2 trials
Hemodialysis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nafamostat Mesylate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- EEnsysce Biosciences